Cybrexa Therapeutics

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform. Our alphalex™ platform allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors. It enables antigen-independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. Cybrexa is able to:

- Rapidly bring novel compounds with robust IP to pivotal studies

- Enable highly potent drugs and combination therapies that are currently limited by toxicity

The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021. CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid safety profile demonstrated to date in preclinical studies.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
CBX-12
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Cybrexa Therapeutics